« Back Clinical Radiology

Article in Press

FDG PET/CT in oncology: “raising the bar”

  • C.N. Patel

      Affiliations

    • Departments of Radiology & Nuclear Medicine, Churchill Hospital, Oxford Radcliffe NHS Trust, Oxford, UK
    • ,
  • A.R. Goldstone

      Affiliations

    • Departments of Radiology & Nuclear Medicine, St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, UK
    • ,
  • F.U. Chowdhury

      Affiliations

    • Departments of Radiology & Nuclear Medicine, St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, UK
    • ,
  • A.F. Scarsbrook

      Affiliations

    • Departments of Radiology & Nuclear Medicine, St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, UK
    • Corresponding Author InformationGuarantor and correspondent: Departments of Radiology and Nuclear Medicine, St James's Institute of Oncology, St James's University Hospital, Beckett Street, Leeds LS9 7TF, UK. Tel.: +44 113 206 8212; fax: +44 113 206 8228.

Received 2 December 2009 ,Revised 23 December 2009 ,Accepted 5 January 2010. Published online 14 June 2010 Corrected Proof

References 

  1. Gambhir SS, Czernin J, Schwimmer J, et al. A tabulated summary of the FDG PET literature. J Nucl Med. 2001;42(Suppl.):1S–93S
  2. Antoch G, Saoudi N, Kuehl H, et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol. 2004;22:4357–4368
  3. von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: current applications and future directions. Radiology. 2006;238:405–422
  4. Blodgett TM, Meltzer CC, Townsend DW. PET/CT: form and function. Radiology. 2007;242:360–385
  5. Poeppel TD, Krause BJ, Heusner TA, et al. PET/CT for staging and follow-up of patients with malignancy. Eur J Radiol. 2009;70:382–392
  6. Board of the Faculty of Clinical Radiology . PET-CT in the UK: a strategy for development and integration of a leading edge technology within routine clinical practice. London: The Royal College of Radiologists; 2005;
  7. Committee for Indications for PET-CT . Oncology FDG PET-CT scan referral criteria. London: UK: PET/CT Advisory Board; 2009;
  8. Hilner BE, Siegel BA, Liu D, et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the national oncologic PET registry. J Clin Oncol. 2008;26:2155–2161
  9. Beyer T, Townsend DW. Putting “clear” into nuclear medicine: a decade of PET/CT development. Eur J Nucl Med Mol Imaging. 2006;33:857–861
  10. Beyer T, Townsend DW, Brun T, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med. 2000;41:1369–1379
  11. Hany TF, Steinert HC, Goerres GW, et al. PET diagnostic accuracy: improvement with in-line PET-CT system: initial results. Radiology. 2002;225:575–581
  12. Mittra E, Quon A. PET/CT: the current technology and applications. Radiol Clin North Am. 2009;47:147–160
  13. Kadrmas DJ, Casey ME, Conti M, et al. Impact of time-of-flight on PET tumor detection. J Nucl Med. 2009;50:1315–1323
  14. Williams G, Kolodny GM. Suppression of myocardial 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. AJR Am J Roentgenol. 2008;190:W151–W156
  15. Williams G, Kolodny GM. Method for decreasing uptake of 18F-FDG by hypermetabolic brown adipose tissue on PET. AJR Am J Roentgenol. 2008;190:1406–1409
  16. Tatsumi M, Engles JM, Ishimori T, et al. Intense (18)F-FDG uptake in brown fat can be reduced pharmacologically. J Nucl Med. 2004;45:1189–1193
  17. Blodgett T. Best practices in PET/CT: consensus on performance of positron emission tomography-computed tomography. Semin Ultrasound CT MRI. 2008;29:236–241
  18. Hamberg LM, Hunter GJ, Alpert NM, et al. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification. J Nucl Med. 1994;35:1308–1312
  19. Alkhawaldeh K, Bural G, Kumar R. Impact of dual-time-point (18)F-FDG PET imaging and partial volume correction in the assessment of solitary pulmonary nodules. Eur J Nucl Med Mol Imaging. 2008;35:246–252
  20. Zytoon AA, Murakami K, El-Kholy MR, et al. Dual time point FDG-PET/CT imaging… Potential tool for diagnosis of breast cancer. Clin Radiol. 2008;63:1213–1227
  21. Lodge MA, Lucas JD, Marsden PK, et al. A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med. 1999;26:22–30
  22. Zhuang H, Pourdehnad M, Lambright ES, et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001;42:1412–1417
  23. Chen YM, Huang G, Sun XG, et al. Optimizing delayed scan time for FDG PET: comparison of the early and late delayed scan. Nucl Med Commun. 2008;29:425–430
  24. Anon . Notes for guidance on the clinical administration of radiopharmaceuticals and use of sealed radioactive sources. Oxon: Administration of Radioactive Substances Advisory Committee; March 2006;
  25. Alessio AM, Kinahan PE, Manchanda V, et al. Weight-based, low-dose pediatric whole-body PET/CT protocols. J Nucl Med. 2009;50:1570–1577
  26. Fahey FH. Dosimetry of pediatric PET/CT. J Nucl Med. 2009;50:1483–1491
  27. Huang B, Law MW, Khong P. Whole-body PET/CT scanning: estimation of radiation dose and cancer risk. Radiology. 2009;251:166–174
  28. Brix G, Lechel U, Glatting G, et al. Radiation exposure of patients undergoing whole body dual modality 18F FDG PET/CT examinations. J Nucl Med. 2005;46:608–613
  29. McCollough CH, Primak AN, Braun N, et al. Strategies for reducing radiation dose in CT. Radiol Clin North Am. 2009;47:27–40
  30. Masuda Y, Kondo C, Matsuo Y, et al. Comparison of imaging protocols for 18F-FDG PET/CT in overweight patients: optimizing scan duration versus administered dose. J Nucl Med. 2009;50:844–848
  31. Nehmeh SA, Erdi YE, Ling CC, et al. Effect of respiratory gating on quantifying PET images of lung cancer. J Nucl Med. 2002;43:876–881
  32. Lupi A, Zaroccolo M, Salgarello M, et al. The effect of 18F-FDG PET/CT respiratory gating on detected metabolic activity in lung lesions. Ann Nucl Med. 2009;23:191–196
  33. Erdi Y, Nehmeh SA, Pan T, et al. The CT motion quantification of lung lesions and its impact on PET-measured SUVs. J Nucl Med. 2004;45:1287–1292
  34. Beyer T, Antoch G, Blodgett T, et al. Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging. 2003;30:588–596
  35. Osman MM, Cohade C, Nakamoto Y, et al. Clinically significant inaccurate localization of lesions with PET/CT: frequency in 300 patients. J Nucl Med. 2003;44:240–243
  36. Beyer T, Antoch G, Muller S, et al. Acquisition protocol considerations for combined PET/CT imaging. J Nucl Med. 2004;45:25S–35S
  37. Zhao B, Yang Y, Li T, et al. Image-guided respiratory-gated lung stereotactic body radiotherapy: which target definition is optimal?. Med Phys. 2009;36:2248–2257
  38. Miles KA. PET-CT in oncology: making the most of CT. Cancer Imaging. 2008;4:S87–S93
  39. Von Schulthess GK. Integrated modality imaging with PET-CT and SPECT-CT: CT issues. Eur Radiol. 2005;15:S121–S126
  40. Antoch G, Freudenberg LS, Beyer T, et al. To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT. J Nucl Med. 2004;45:56S–65S
  41. Burger C, Georres G, Schoenes S, et al. PET attenuation coefficients from CT images: experimental evaluation of the transformation of CT into PET 511-keV attenuation coefficients. Eur J Nucl Med. 2002;29:922–927
  42. Kinahan PE, Townsend DW, Beyer T, et al. Attenuation correction for a combined 3D PET/CT scanner. Med Phys. 1998;25:2046–2053
  43. Antoch G, Freudenberg LS, Egelhof T, et al. Focal tracer uptake: a potential artifact in cedual-modality PET/CT scans. J Nucl Med. 2002;43:1339–1342
  44. Bunyaviroch T, Turkington TG, Wong TZ, et al. Quantitative effects of contrast enhanced CT attenuation correction on PET SUV measurements. Mol Imaging Biol. 2008;10:107–113
  45. Nehmeh SA, Erdi YE, Kalaigian H, et al. Correction for oral contrast artifacts in CT attenuation-corrected PET images obtained by combined PET/CT. J Nucl Med. 2003;44:1940–1944
  46. Dizendorf E, Hany TF, Buck A, et al. Cause and magnitude of the error induced by oral CT contrast agent in CT-based attenuation correction of PET emission studies. J Nucl Med. 2003;44:732–738
  47. Antoch G, Kuehl H, Kanja J, et al. Dual-modality PET/CT scanning with negative oral contrast agent to avoid contrast-induced artefacts: introduction and evaluation. Radiology. 2004;230:879–885
  48. Groves AM, Kayani I, Dickson JC, et al. Oral contrast medium in PET/CT: should you or shouldn't you?. Eur J Nucl Med Mol Imaging. 2005;32:1160–1166
  49. Blodgett T, Fukui MB, Snyderman CH, et al. Combined PET-CT in the head and neck: part I. Physiologic, altered physiologic, and artifactual FDG uptake. RadioGraphics. 2005;25:897–912
  50. Yau YY, Chan WS, Tam YM, et al. Application of intravenous contrast in PET/CT: does it really introduce significant attenuation correction error?. J Nucl Med. 2005;46:283–291
  51. Mawlawi O, Erasmus JJ, Munden RF, et al. Quantifying the effect of IV contrast media on integrated PET/CT: clinical evaluation. AJR Am J Roentgenol. 2006;186:308–319
  52. Badiee S, Franc BL, Webb EM, et al. Role of IV iodinated contrast material in 18F-FDG PET/CT of liver metastases. AJR Am J Roentgenol. 2008;191:1436–1439
  53. Pfannenberg AC, Aschoff P, Brechtel K, et al. Value of contrast-enhanced multiphase CT in combined PET/CT protocols for oncological imaging. Br J Radiol. 2007;80:437–445
  54. Rodríguez-Vigil B, Gómez-León N, Pinilla I, et al. PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT. J Nucl Med. 2006;47:1643–1648
  55. Pfannenberg AC, Aschoff P, Brechtel K, et al. Low dose non-enhanced CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2007;34:36–44
  56. Strobel K, Heinrich S, Bhure U, et al. Contrast-enhanced 18F-FDG PET/CT: 1-stop-shop imaging for assessing the resectability of pancreatic cancer. J Nucl Med. 2008;49:1408–1413
  57. Kumar R, Das CJ. Hybrid PET-dynamic CECT in the management of breast cancer. Eur J Nucl Med Mol Imaging. 2009;36:413–415
  58. Veit-Haibach P, Treyer V, Strobel K, et al. Feasibility of integrated CT-liver perfusion in routine FDG PET/CT. Abdom Imaging. 2009;[Epub ahead of print]
  59. Kuehl H, Veit P, Rosenbaum SJ, et al. Can PET/CT replace separate diagnostic CT for cancer imaging? Optimizing CT protocols for imaging cancers of the chest and abdomen. J Nucl Med. 2007;48(Suppl.):45S–57S
  60. Mah D, Chen CC. Image guidance in radiation oncology treatment planning: the role of imaging technologies on the planning process. Semin Nucl Med. 2008;38:114–118
  61. ICRU . Report 62, prescribing, recording and reporting photon beam therapy. (Supplement to ICRU Report 50). Washington DC: International commission on Radiation Units and Measurements; 1999;
  62. Caldwell CB, Mah K, Ung YC, et al. Observer variation in contouring gross tumor volume in patients with poorly defined non-small cell lung tumors on CT: the impact of 18FDG-hybrid PET fusion. Int J Radiat Oncol Biol Phys. 2001;51:923–931
  63. Riegel AC, Berson AM, Destian S, et al. Variability of gross tumor volume delineation in head-and-neck cancer using CT and PET/CT fusion. Int J Radiat Oncol Biol Phys. 2006;65:726–732
  64. Khoo VS, Joon DL. New developments in MRI for target volume delineation in radiotherapy. Br J Radiol. 2006;79:S2–S15
  65. Heron DE, Andrade RS, Beriwal S, et al. PET-CT in radiation oncology. The impact on diagnosis, treatment planning, and assessment of treatment response. Am J Clin Oncol. 2008;31:352–362
  66. Ford EC, Herman J, Yorke E, et al. 18F-FDG PET/CT for image-guided and intensity modulated radiotherapy. J Nucl Med. 2009;50:1655–1665
  67. Breen SL, Publicover J, De Silva S, et al. Intraobserver and interobserver variability in GTV delineation on FDG-PET-CT images of head and neck cancers. Int J Radiat Oncol Biol Phys. 2007;68:763–770
  68. Dizendorf E, Baimert B, Von Schulthess G, et al. Impact of whole-body 18F-FDG on staging and managing patients for radiation therapy. J Nucl Med. 2003;44:24–32
  69. Mageras G, Yorke E. Deep inspiration breath-hold and respiratory gating strategies for reducing organ motion in radiation treatment. Semin Radiat Oncol. 2004;14:65–75
  70. Nehmeh SA, Erdi YE, Pan T, et al. Four-dimensional (4D) PET/CT imaging of the thorax. Med Phys. 2007;31:3179–3186
  71. Greco C, Rosenzweig K, Cascini GL, et al. Current status of PET/CT for tumour volume definition in radiotherapy treatment planning for non-small cell lung cancer (NSCLC). Lung Cancer. 2007;57:125–134
  72. Ahn PH, Garg MK. Positron emission tomography/computed tomography for target delineation in head and neck cancers. Semin Nucl Med. 2008;38:141–148
  73. MacManus M, Nestle U, Rosenzweig KE, et al. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. Radiother Oncol. 2009;91:85–94
  74. Nestle U, Kemp S, Schaefer-Schuler A, et al. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-small cell lung cancer. J Nucl Med. 2005;46:1342–1348
  75. Cannon DM, Lee NY. Recurrence in region of spared parotid gland after definitive intensity-modulated radiotherapy for hand and neck cancer. Int J Radiat Oncol Biol Phys. 2008;70:660–665
  76. WHO . Who handbook for reporting results of cancer treatment. Offset publication No. 48. Geneva: World Health Organization; 1979;
  77. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–216
  78. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guidelines (version 1.1). Eur J Cancer. 2009;45:228–247
  79. Zhao B, Schwartz LH, Moskowitz C, et al. Computerized quantification of tumor response in lung cancer: initial results. Radiology. 2006;241:892–898
  80. Eisenhauer EA. Response evaluation: beyond RECIST. Ann Oncol. 2007;18:S29–S32
  81. Zhao B, Schwartz LH, Larson SM. Imaging surrogates of tumor response to therapy: anatomic and functional biomarkers. J Nucl Med. 2009;50:239–249
  82. Bos R, van Der Hoeven JJ, van Der Wall E, et al. Biologic correlates of 18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;20:379–387
  83. Wahl RL, Zasadny K, Helvie M, et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol. 1993;11:2101–2111
  84. Weber WA. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med. 2005;46:983–995
  85. Minn H, Paul R, Ahonen A. Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose. J Nucl Med. 1988;29:1521–1525
  86. Kasamon YL, Wahl RL. FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma. Curr Opin Oncol. 2008;20:206–219
  87. Hicks RJ. The role of PET in monitoring therapy. Cancer Imaging. 2005;5:51–57
  88. Boellaard R. Standards for PET image acquisitions and quantitative data analysis. J Nucl Med. 2009;50(Suppl. 1):11S–20S
  89. Roedl JB, Halpern EF, Colen RR, et al. Metabolic tumor width parameters as determined on PET/CT predict disease-free survival and treatment response in squamous cell carcinoma of the esophagus. Mol Imaging Biol. 2009;11:54–60
  90. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer. 1999;35:1773–1782
  91. Shankar LK, Hoffman JM, Bacharach S, et al. Guidelines for the use of 18FDG PET as an indicator of therapeutic response in patients in national cancer institute trials. J Nucl Med. 2006;47:1059–1066
  92. Juweid ME, Wiseman GA, Vose JM, et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol. 2005;23:4652–4661
  93. Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl. 1):122S–150S
  94. Povoski SP, Neff RL, Mojzisik CM, et al. A comprehensive overview of radioguided surgery using gamma detection probe technology. World J Surg Oncol. 2009;7:11
  95. Essner R, Daghighian F, Giuliano AE. Advances in FDG PET probe in surgical oncology. Cancer J. 2002;8:100–108
  96. Schillaci O. PET probes and oncological surgery: a productive new marriage for nuclear medicine?. Eur J Med Mol Imaging. 2007;34:1530–1533
  97. Piert M, Burian M, Meisetschlager G, et al. Positron detection for the intraoperative localisation of cancer deposits. Eur J Nuc Med Mol Imaging. 2007;34:1534–1544
  98. Gulec SA, Hoenie E, Hostetter R, et al. PET probe-guided surgery: applications and clinical protocol. World J Surg Oncol. 2007;5:65
  99. Nwogu C, Fischer G, Tan D, et al. Radioguided detection of lymph node metastasis in non-small cell lung cancer. Ann Thorac Surg. 2006;82:1815–1820
  100. Andersen PA, Chakera AH, Klausen TL, et al. Radiation exposure to surgical staff during F-18-FDG guided cancer surgery. Eur J Nucl Med Mol Imaging. 2008;35:624–629
  101. Englmeier KH, Seemann MD. Multimodal virtual bronchoscopy using PET/CT images. Comp Aided Surg. 2008;13:106–113
  102. Seemann MD, Schaefer JF, Englmeier KH. Virtual positron emission tomography/computed tomography-bronchoscopy: possibilities, advantages and limitations of clinical application. Eur Radiol. 2007;17:709–715
  103. Quon A, Napel S, Beaulieu CF, et al. Flying through“ and ”flying around" a PET/CT scan: pilot study and development of 3D integrated 18F-FDG PET/CT for virtual bronchoscopy and colonoscopy. J Nucl Med. 2006;47:1081–1087
  104. Antoch G, Bockisch A. Combined PET/MRI: a dimension in whole-body oncology imaging?. Eur J Nucl Med Mol Imaging. 2009;36(Suppl. 1):S113–S120
  105. Schlemmer HP, Pichler BJ, Schmand M, et al. Simultaneous MR/PET imaging of the human brain: a feasibility study. Radiology. 2008;248:1028–1035
  106. Pichler BJ, Wehrl HF, Kolb A, et al. Positron emission tomography/magnetic resonance imaging: the next generation of multimodality imaging?. Semin Nucl Med. 2008;38:199–208
  107. Delso G, Ziegler S. PET/MRI system designs. Eur J Nucl Med Mol Imaging. 2009;36(Suppl. 1):S86–S92
  108. Von Schulthess GK, Schlemmer HP. A look ahead: PET/MR versus PET/CT. Eur J Nucl Med Mol Imaging. 2009;36(Suppl. 1):S3–S9
  109. Hofmann M, Pichler B, Schölkopf B, et al. Towards quantitative PET/MRI: a review of MR-based attenuation correction techniques. Eur J Nucl Med Mol Imaging. 2009;36(Suppl. 1):S93–104
  110. Schlemmer HP, Pichler BJ, Krieg R, et al. An integrated MR/PET system: prospective applications. Abdom Imaging. 2009;34:668–674
  111. Hicks RJ, Lau EW. PET/MR: a different spin from under the rim. Eur J Nucl Med Mol Imaging. 2009;36(Suppl. 1):S10–S14
  112. Domingues RC, Carneiro MP, Lopes FC, et al. Whole-body MRI and FDG PET fused images for evaluation of patients with cancer. AJR Am J Roentgenol. 2009;192:1012–1020

PII: S0009-9260(10)00031-0

doi: 10.1016/j.crad.2010.01.003

« Back Clinical Radiology

Article in Press

Article Tools

* Image Usage & Resolution